Navigation Links
Battling bacteria in the blood: Researchers tackle deadly infections
Date:11/11/2008

ANN ARBOR, Mich. It's a leading cause of death, but no one knows for sure how and why it happens. It's a major source of health care costs, adding days or weeks to the hospital stays and lost work time of millions of people. But no one fully understands how best to fight it.

"It" is bacterial infection in the blood, also called bacteremia, and it's a major part of the very serious illness called sepsis.

It's an infection that will turn deadly in some people, especially cancer patients and others with weak immune systems while being easily treated in others. It doesn't get much public attention, although it affects ten times more Americans than breast cancer. Hospitals struggle mightily, but often futilely, to prevent and treat it every day.

Now, new research by a University of Michigan team and their colleagues is tackling the problem at its most basic level, in hopes of finding new and more effective ways to treat bacteremia and sepsis.

In a research paper published in the November issue of the journal Shock, and recent papers in the journals Bulletin of Mathematical Biology and Academic Emergency Medicine, the team describes new computer-based models of bloodstream infection that may help guide the development of new treatments.

The models use complex mathematical techniques, but have been validated by laboratory experiments in mice and in engineered bloodstream models.

The new findings give more information than ever before about how bacteria act within the blood vessels of the body, and how they might be filtered out of the blood and into organs where the immune system can attack and kill them.

Now, this model of how bacteremia occurs in "real world" of the fast-moving bloodstream rather than a placid Petri dish or test tube can be put to work to study how best to combat or prevent bacteria in the blood.

John Younger, M.D., M.S., an associate professor of emergency medici
'/>"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Battling virus disease of watermelon with bottlegourds
2. Battling diabetes with beta cells
3. Shuttle brings space-grown strep bacteria back for study
4. The worlds oldest bacteria
5. Bacteria from sponges make new pharmaceuticals
6. Boston University biomedical engineers find chink in bacterias armor
7. University of Leicester scientists discover technique to help friendly bacteria
8. Spaceflight shown to alter ability of bacteria to cause disease
9. A tiny pinch from a z-ring helps bacteria cells divide
10. Legionnaires bacterial proteins work together to survive
11. Scripps research team blocks bacterial communication system to prevent deadly staph infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... the battle against AIDS and a major development in the ... protein that prevents the virus from entering cells. This protein ... that protects cells from viruses, except the man-made version does ... needed to inhibit AIDS. This discovery was published in the ...
... Reducing Emissions from Deforestation and Forest Degradation ... that aims to financially compensate landowners and stewards ... as promoting forest conservation, sustainable forest management and ... and implemented correctly, REDD+ has the potential to ...
... RIVERSIDE, Calif. What are transposable elements, what role do ... they comprise? Is there an explanation for the genetic diversity ... spotted? What is the genetic basis for this spotted trait? ... a free public lecture at 6 p.m., Thursday, April 14, at ...
Cached Biology News:Intelligent design: Engineered protein fragment blocks the AIDS virus from entering cells 2REDD+, Technical, Socioeconomic and Political Dimensions 2REDD+, Technical, Socioeconomic and Political Dimensions 3Teaching old genomes new tricks 2
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... HUYA Bioscience International, a leader in globalizing ... the Shenzhen Polytechnic School of Applied Chemistry and Biotechnology ... in accelerating the development of novel drugs, discovered from ... The agreement provides HUYA with access to and ...
... NephroGenex, Inc., a privately held drug development company, ... the FDA on the design of a new Phase ... nephropathy patients.  This Subpart H program uses a novel ... (SCr), and provides for an accelerated regulatory pathway to ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a ... extracellular matrix for the diabetes, cancer, dermatology and ... third quarter of 2011 and discussed recent business progress. ... past few months highlight the progress at Halozyme on ...
Cached Biology Technology:HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology 2HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology 3NephroGenex Reaches Agreement with the FDA on a Subpart H Phase 3 Program for Pyridorin™ 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 7
...
Anti-MMP-7, aminoterminal end active enzyme; rabbit host...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: